Injectable placenta extract for fatty liver disease
Part of Digestive system clinical trials.
This trial tests an injectable medication made from human placenta to see if it can improve liver health in people with fatty liver disease (from alcohol or other causes). It may help lower liver enzyme levels and reduce liver damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 70 years old.
- You have been diagnosed with alcoholic fatty liver disease or non-alcoholic fatty liver disease.
- Your ALT level (a liver enzyme test) is between 60 and 200 IU/L.
- You have not had serious liver problems (like bleeding from the esophagus, fluid buildup, or liver cancer) in the past year.
- You do not have hepatitis B or C (unless treated successfully), or other active infections like tuberculosis.
- You agree to avoid certain medications and alcohol during the trial, and use effective birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether plasmapheresis (a blood-cleaning procedure) can help people with severe drug-induced liver injury who also have a chronic liver condition. If you qualify, you would receive this treatment to try to reduce liver damage and improve recovery.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests whether a new drug called AZD2389 is safe and well-tolerated in adults with steatotic liver disease (fatty liver) that has progressed to advanced scarring. The trial aims to see if this drug might help slow or improve liver damage in people with this condition.
This trial tests a device that uses a specially pig liver to help people with severe, sudden liver failure who cannot get a transplant. It aims to support the liver until it recovers or a transplant becomes possible.
This trial tests a potential new medicine (NNC4005-0001) for liver disease in adults who have extra body weight and excess fat in their liver. It aims to see if the medicine can help improve liver health.
This trial studies whether LivPhcD capsules can improve fatty liver disease and checks for side effects. It may help people with non-alcohol-related fatty liver disease who meet specific liver-scanning and lab results.
Hear when a new Chronic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.